In the last trading session, 4.56 million shares of the ImmunityBio Inc (NASDAQ:IBRX) were traded, and its beta was 1.19. Most recently the company’s share price was $5.27, and it changed around $0.36 or 7.33% from the last close, which brings the market valuation of the company to $3.55B. IBRX currently trades at a discount to its 52-week high of $6.93, offering almost -31.5% off that amount. The share price’s 52-week low was $1.25, which indicates that the current value has risen by an impressive 76.28% since then. We note from ImmunityBio Inc’s average daily trading volume that its 3-month average coming to 4.17 million.
ImmunityBio Inc (NASDAQ:IBRX) trade information
Instantly IBRX has showed a green trend with a performance of 7.33% at the end of last trading. The performance over the last five days has remained in the green territory. The company’s shares are currently up 4.98% year-to-date, but still up 3.13% over the last five days. On the other hand, ImmunityBio Inc (NASDAQ:IBRX) is -12.02% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $8, which translates to bulls needing to increase their stock price by 34.13% from its current value. Analyst projections state that IBRX is forecast to be at a low of $8 and a high of $8.
ImmunityBio Inc (IBRX) estimates and forecasts
ImmunityBio Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 273.76 percent over the past six months and at a 31.31% annual growth rate that is well above the industry average of 13.30%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 40.70% in revenue this quarter, and will report an increase of 46.90% in the next quarter. The year-over-year growth rate is expected to be 1,456.30%, up from the previous year.
Consensus estimates provided by 1 financial analysts predict the company will bring in an average of $20k in revenue for the current quarter. 1 analysts expect ImmunityBio Inc to make $520k in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $360k and $41k respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -94.40%. Forecasts for the next quarter put sales growth at 1,168.30%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 1.17%. ImmunityBio Inc earnings are expected to increase by 40.87% in 2024, but the outlook is negative -1.70% per year for the next five years.
IBRX Dividends
ImmunityBio Inc’s next quarterly earnings report is expected to be released in May.
